ECSP11010847A - Métodos para tratar la talasemia - Google Patents
Métodos para tratar la talasemiaInfo
- Publication number
- ECSP11010847A ECSP11010847A EC2011010847A ECSP11010847A ECSP11010847A EC SP11010847 A ECSP11010847 A EC SP11010847A EC 2011010847 A EC2011010847 A EC 2011010847A EC SP11010847 A ECSP11010847 A EC SP11010847A EC SP11010847 A ECSP11010847 A EC SP11010847A
- Authority
- EC
- Ecuador
- Prior art keywords
- talasemia
- treat
- methods
- thalassemia
- effective amount
- Prior art date
Links
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 101150009057 JAK2 gene Proteins 0.000 abstract 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 abstract 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 abstract 1
- 208000002903 Thalassemia Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente invención se proporciona un método para tratar, mejorar, o retrasar al menos un síntoma de un trastorno sanguíneo genético, por ejemplo, anemia drepanocítica o talasemia, en un paciente que lo necesite, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2. También se proporciona en parte un método para reducir un bazo dilatado en un paciente que padece talasemia, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8623308P | 2008-08-05 | 2008-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11010847A true ECSP11010847A (es) | 2011-07-29 |
Family
ID=41581108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011010847A ECSP11010847A (es) | 2008-08-05 | 2011-02-28 | Métodos para tratar la talasemia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110269721A1 (es) |
| EP (1) | EP2355827A2 (es) |
| JP (1) | JP2011530517A (es) |
| KR (1) | KR20110053347A (es) |
| CN (1) | CN102112131A (es) |
| AU (1) | AU2009279825A1 (es) |
| BR (1) | BRPI0917575A2 (es) |
| CA (1) | CA2732791A1 (es) |
| CL (1) | CL2011000242A1 (es) |
| CO (1) | CO6351728A2 (es) |
| CR (1) | CR20110115A (es) |
| DO (1) | DOP2011000044A (es) |
| EC (1) | ECSP11010847A (es) |
| IL (1) | IL211061A0 (es) |
| MA (1) | MA32611B1 (es) |
| MX (1) | MX2011001426A (es) |
| NI (1) | NI201100031A (es) |
| RU (1) | RU2011108563A (es) |
| SV (1) | SV2011003823A (es) |
| WO (1) | WO2010017122A2 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456176B2 (en) | 2004-04-08 | 2008-11-25 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| US7652051B2 (en) | 2004-08-25 | 2010-01-26 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US7528143B2 (en) | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8486941B2 (en) | 2007-03-12 | 2013-07-16 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| WO2012071612A1 (en) * | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| CN103664799A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| JP6433974B2 (ja) | 2013-03-14 | 2018-12-05 | トレロ ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法 |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
| IL307931A (en) * | 2016-04-15 | 2023-12-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| WO2018183923A1 (en) * | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CA3081946A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in preventing or treating blood disorders |
| US20210213014A1 (en) * | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
| BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
| CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| WO2020023910A1 (en) | 2018-07-26 | 2020-01-30 | Tolero Pharmaceuticals, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| US12187686B2 (en) * | 2018-09-07 | 2025-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-JAK2 inhibitors |
| AU2020221247B2 (en) | 2019-02-12 | 2024-12-12 | Sumitomo Pharma America, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| CN112778282B (zh) * | 2021-01-06 | 2022-07-22 | 温州医科大学 | 一种嘧啶类小分子化合物及其应用 |
| JP2026509318A (ja) | 2022-10-31 | 2026-03-18 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | 骨髄増殖性新生物を治療するためのｐｉｍ１阻害剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528143B2 (en) * | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
-
2009
- 2009-08-03 RU RU2011108563/15A patent/RU2011108563A/ru not_active Application Discontinuation
- 2009-08-03 BR BRPI0917575A patent/BRPI0917575A2/pt not_active IP Right Cessation
- 2009-08-03 CA CA2732791A patent/CA2732791A1/en not_active Abandoned
- 2009-08-03 WO PCT/US2009/052544 patent/WO2010017122A2/en not_active Ceased
- 2009-08-03 AU AU2009279825A patent/AU2009279825A1/en not_active Abandoned
- 2009-08-03 EP EP09741504A patent/EP2355827A2/en not_active Withdrawn
- 2009-08-03 CN CN2009801303954A patent/CN102112131A/zh active Pending
- 2009-08-03 JP JP2011522136A patent/JP2011530517A/ja active Pending
- 2009-08-03 US US13/057,133 patent/US20110269721A1/en not_active Abandoned
- 2009-08-03 MX MX2011001426A patent/MX2011001426A/es not_active Application Discontinuation
- 2009-08-03 KR KR1020117005224A patent/KR20110053347A/ko not_active Withdrawn
-
2011
- 2011-02-01 SV SV2011003823A patent/SV2011003823A/es not_active Application Discontinuation
- 2011-02-02 NI NI201100031A patent/NI201100031A/es unknown
- 2011-02-03 IL IL211061A patent/IL211061A0/en unknown
- 2011-02-03 DO DO2011000044A patent/DOP2011000044A/es unknown
- 2011-02-04 CL CL2011000242A patent/CL2011000242A1/es unknown
- 2011-02-28 EC EC2011010847A patent/ECSP11010847A/es unknown
- 2011-03-02 CR CR20110115A patent/CR20110115A/es not_active Application Discontinuation
- 2011-03-04 MA MA33672A patent/MA32611B1/fr unknown
- 2011-03-04 CO CO11026653A patent/CO6351728A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2011000044A (es) | 2011-04-30 |
| WO2010017122A3 (en) | 2010-04-08 |
| BRPI0917575A2 (pt) | 2019-09-24 |
| JP2011530517A (ja) | 2011-12-22 |
| MA32611B1 (fr) | 2011-09-01 |
| CO6351728A2 (es) | 2011-12-20 |
| CR20110115A (es) | 2011-06-03 |
| NI201100031A (es) | 2011-09-26 |
| CL2011000242A1 (es) | 2011-04-08 |
| AU2009279825A1 (en) | 2010-02-11 |
| MX2011001426A (es) | 2011-03-21 |
| CA2732791A1 (en) | 2010-02-11 |
| SV2011003823A (es) | 2011-08-15 |
| EP2355827A2 (en) | 2011-08-17 |
| US20110269721A1 (en) | 2011-11-03 |
| WO2010017122A2 (en) | 2010-02-11 |
| RU2011108563A (ru) | 2012-09-10 |
| KR20110053347A (ko) | 2011-05-20 |
| IL211061A0 (en) | 2011-04-28 |
| CN102112131A (zh) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6351728A2 (es) | Metodos para tratar la talasemia | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
| WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
| WO2010009342A3 (en) | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | |
| EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
| EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
| EA201690111A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
| WO2008063157A3 (en) | A nanoparticle-based anticoagulant | |
| WO2007098099A3 (en) | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | |
| MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
| BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
| EA201490614A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения | |
| WO2012170945A3 (en) | Methods for modulating kallikrein (klkb1) expression | |
| EA201001749A1 (ru) | Способ лечения недифференцированного артрита | |
| AU2010279892A8 (en) | Humanized anti-amyloid-b oligomer antibody | |
| WO2013028070A3 (en) | Compounds for use in boosting coagulation | |
| WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
| TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| UY33332A (es) | Compuestos de triazol como inhibidores de ksp |